New England Journal of Medicine December 06, 2001

A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure

Cohn JN, Tognoni G

Bottom Line

The Val-HeFT trial demonstrated that adding the angiotensin-receptor blocker valsartan to standard therapy in patients with heart failure with reduced ejection fraction significantly reduced overall morbidity—driven by a decrease in heart failure hospitalizations—but did not improve overall survival.

Key Findings

1. No significant difference in all-cause mortality: 19.7% in the valsartan group vs. 19.4% in the placebo group (RR 1.02, 97.5% CI 0.88-1.18, p=0.80) [14.1.5].

2. The combined co-primary endpoint of morbidity and mortality was significantly reduced with valsartan (28.8% vs. 32.1%; RR 0.87, 97.5% CI 0.77-0.97, p=0.009).

3. This reduction was primarily driven by a 24% relative decrease in hospitalizations for worsening heart failure (13.8% vs. 18.2%, p<0.001).

4. Post-hoc subgroup analysis suggested an adverse interaction in patients receiving "triple therapy" (ACE inhibitor, beta-blocker, and valsartan), showing a trend toward increased morbidity and mortality, whereas those on neither ACE inhibitor nor beta-blocker derived the greatest mortality benefit.

5. Valsartan significantly improved NYHA class, ejection fraction, and signs and symptoms of heart failure compared with placebo.

Study Design

Design

Randomized Controlled Trial

Double-Blind

Sample

5,010

Patients

Duration

23 mo

Median

Setting

Multicenter, multinational

Population Patients with chronic heart failure (NYHA class II to IV) and left ventricular ejection fraction <40%, receiving standard background therapy.

Intervention Valsartan (target dose 160 mg twice daily)

Comparator Placebo twice daily

Outcome All-cause mortality and a composite of all-cause mortality and heart failure morbidity (cardiac arrest with resuscitation, HF hospitalization, or IV inotropes/vasodilators for ≥4 hours).

Study Limitations

• The study did not demonstrate an overall mortality benefit; the primary efficacy was driven entirely by morbidity (heart failure hospitalizations).

• Only 35% of the trial population was on baseline beta-blocker therapy, making it less reflective of modern, robust guideline-directed medical therapy.

• The post-hoc subgroup analysis suggesting harm with "triple therapy" (ACE inhibitor, ARB, and beta-blocker) caused significant clinical confusion and restricted combining these agents, though it was likely a statistical artifact as later trials like CHARM-Added did not find this hazard.

Clinical Significance

Val-HeFT established ARBs as an effective therapy for reducing morbidity in patients with heart failure with reduced ejection fraction, particularly demonstrating their utility in reducing hospitalizations when added to standard background therapy. It cemented the role of ARBs as a primary alternative for patients intolerant to ACE inhibitors.

Historical Context

Published in 2001, Val-HeFT was a landmark trial evaluating the addition of an ARB to background ACE inhibitor therapy in patients with heart failure. While CONSENSUS and SOLVD had firmly established ACE inhibitors, the phenomenon of "ACE escape" suggested that ARBs might provide additional blockade of angiotensin II. Val-HeFT was the first large trial to show that adding an ARB to an ACEi reduced morbidity, paving the way for multidrug neurohormonal blockade, although its subgroup data temporarily caused hesitancy around combining ACE inhibitors, ARBs, and beta-blockers.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What is the pathophysiological rationale for adding an Angiotensin-Receptor Blocker (ARB) like valsartan to a heart failure regimen that already includes an ACE inhibitor?

Key Response

This question explores the concept of 'angiotensin escape.' While ACE inhibitors block the primary pathway of Angiotensin II production, alternative enzymes (like chymase) can still generate Angiotensin II. ARBs directly block the AT1 receptor, theoretically providing a more complete blockade of the deleterious effects of the renin-angiotensin-aldosterone system (RAAS) in heart failure.

Resident

Based on the Val-HeFT trial, how does the addition of valsartan affect the primary endpoints of mortality and morbidity, and what specific clinical outcome drove the morbidity benefit?

Key Response

This tests foundational clinical knowledge of the trial's results. Valsartan significantly reduced the combined endpoint of morbidity and mortality, but this was entirely driven by a reduction in heart failure hospitalizations (morbidity). Unlike ACE inhibitors and beta-blockers, valsartan did not improve overall survival (mortality) in this trial.

Fellow

The Val-HeFT trial revealed a concerning signal in a specific subgroup of patients receiving 'triple therapy.' What was this subgroup, and how does this finding influence the contemporary pharmacological management of HFrEF?

Key Response

This addresses the nuanced finding that patients taking both an ACE inhibitor and a beta-blocker at baseline appeared to have an adverse outcome (increased mortality/morbidity) when valsartan was added. This taught cardiologists to avoid routine 'triple therapy' (ACEi + ARB + beta-blocker) due to increased risks of hyperkalemia, hypotension, and renal dysfunction without added survival benefit.

Attending

Given that Val-HeFT showed no mortality benefit for valsartan when added to standard therapy, how do you synthesize this trial's findings when teaching trainees about the clinical positioning of ARBs versus ACE inhibitors in heart failure management?

Key Response

This highlights the key teaching point that ARBs are primarily indicated as an alternative for patients who are intolerant to ACE inhibitors (e.g., due to cough or angioedema), rather than as an additive therapy. This prevents unnecessary polypharmacy and mitigates the risk of adverse renal events while achieving effective RAAS blockade.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The controversial finding regarding increased adverse events in the ACE inhibitor plus beta-blocker subgroup was derived from a post-hoc subgroup analysis. What are the statistical limitations of interpreting post-hoc subgroup interactions in a trial like Val-HeFT, and how should future trials be designed to robustly evaluate such combination therapies?

Key Response

This critiques the methodological vulnerability of post-hoc analyses, including multiplicity, false-positive interactions (Type I error), and underpowering. A robust evaluation would require a prospective, factorial design or pre-specified stratification to adequately power and test interaction terms for combination therapies.

Journal Editor

If reviewing Val-HeFT today, how would you critically evaluate the authors' choice of a composite co-primary endpoint (mortality and morbidity) when the hard mortality component showed no benefit, and what reporting standards would you enforce?

Key Response

This focuses on critical appraisal of composite endpoints. A tough reviewer would flag the risk of 'spin,' ensuring the abstract and conclusions do not misleadingly imply a survival benefit. The editorial standard must clearly state that the composite success was driven solely by softer endpoints (hospitalizations) to maintain literature integrity.

Guideline Committee

How did the findings of Val-HeFT regarding the combination of an ACE inhibitor, ARB, and beta-blocker influence ACC/AHA heart failure guidelines, and how does this historical context compare to current guideline recommendations regarding RAAS blockade?

Key Response

Val-HeFT's data led guideline committees to issue a Class III (Harm) recommendation against the routine combined use of an ACE inhibitor, ARB, and beta-blocker due to the lack of mortality benefit and increased adverse effects. Current guidelines have evolved to recommend replacing ACEi/ARBs entirely with ARNIs (sacubitril/valsartan) as a superior strategy, while still maintaining the contraindication against combining ARNIs or ARBs with ACE inhibitors.

Clinical Landscape

Noteworthy Related Trials

1991

SOLVD-Treatment Trial

n = 2,569 · NEJM

Tested

Enalapril

Population

Patients with symptomatic heart failure and reduced ejection fraction

Comparator

Placebo

Endpoint

All-cause mortality

Key result: Enalapril significantly reduced overall mortality and hospitalizations for heart failure compared to placebo.

2003

CHARM-Alternative Trial

n = 2,028 · Lancet

Tested

Candesartan

Population

Symptomatic heart failure patients intolerant to ACE inhibitors

Comparator

Placebo

Endpoint

Cardiovascular death or hospital admission for heart failure

Key result: Candesartan significantly reduced the risk of cardiovascular death or hospital admission for heart failure compared to placebo.

2014

PARADIGM-HF Trial

n = 8,399 · NEJM

Tested

Sacubitril/valsartan

Population

Patients with chronic heart failure with reduced ejection fraction

Comparator

Enalapril

Endpoint

Composite of cardiovascular death or heart failure hospitalization

Key result: Sacubitril/valsartan was significantly superior to enalapril in reducing the risks of death and hospitalization for heart failure.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis